Idiomas Español
Activos compatibles
MRNAc logo

Moderna

Antes de apertura

Abrir Mo

232,84 US$

-en el período seleccionado

+4,40 US$ (+1,93 %)desde el cierre de EE. UU.

Precio onchain
-
Prima / descuento
-
Actualizado Referencia

Diferencias de precio antes de comisiones y costes de ejecución. Comparar precios

Análisis

Can Moderna’s melanoma data drive lasting growth beyond COVID vaccines? They weigh cash burn, manufacturing risk and valuation versus oncology upside.

COVID‑19 vaccine revenue sustainability

The conventional assumption is that the COVID-19 vaccine business settles into a seasonal annuity in the $1–2 billion range, analogous to a severe-flu product.

In the current environment it is not, and the difference is worth roughly $1 billion a year to Moderna's revenue line. The company cannot manage this risk with better science, a better formulation or a lower price.

Moderna, Inc. (MRNA) — The Platform and the Price | Farstar CapitalModerna, Inc. (MRNA) — The Platform and the Price | Farstar Capital

Oncology pipeline validation and commercialization

Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) said a Phase 3 melanoma trial of intismeran plus Keytruda met its recurrence-free survival and distant metastasis-free survival endpoints. Both companies described the improvements as statistically significant and clinically meaningful.

The melanoma Phase 3 result and influenza approval strengthen the platform and diversification claims, while missing effect-size detail, manufacturing complexity, cash burn and financing keep commercialization and per-share value unresolved. What it did not provide was the underlying data: the hazard ratios, the survival curves, the magnitude and durability of the benefit.

Why Is Moderna, Inc. (NASDAQ: MRNA) Stock Up 569% This Year?Why Is Moderna, Inc. (NASDAQ: MRNA) Stock Up 569% This Year?Moderna Is Up About 500% in 2026. Oct. 24 Could Double It or Erase the Rally. – Investment House

Cash burn and path to breakeven

It holds $6.9 billion of cash, equivalents and investments as at 30 June 2026, and guides to $4.7–5.2 billion at year-end. It has committed to reaching cash breakeven in 2028. That commitment requires revenue to roughly double from the 2026 base while cash operating costs stay inside a guided 2027 range of $3.5–3.9 billion.

The company lost $2.82 billion in 2025 and $2.13 billion in the first half of 2026 alone, of which $900 million was a non-recurring litigation settlement. First-half operating cash use improved to $1.16 billion from $1.96 billion a year earlier, but the first-half net loss was $2.13 billion.

Moderna, Inc. (MRNA) — The Platform and the Price | Farstar CapitalModerna, Inc. (MRNA) — The Platform and the Price | Farstar CapitalWhy Is Moderna, Inc. (NASDAQ: MRNA) Stock Up 569% This Year?

Noticias

Token

Token
MRNAc
Acciones por token
1.00000000 MRNA
Contrato
0xb200000000000000000000e215e9b76ecba02468

Consigue Mo

Guárdalo en Mo

Mantén MRNAc en una billetera inteligente de Mo en Base que tú controlas.

Muévelo rápido

Envía MRNAc a otro usuario de Mo sin comisiones, o a cualquier billetera compatible en Base casi al instante.

Tu dinero. Más posibilidades.